Common Contracts
13 similar Employment Agreement contracts by Achillion Pharmaceuticals Inc
EMPLOYMENT AGREEMENTEmployment Agreement • February 11th, 2019 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Pennsylvania
This Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Brian Di Donato (the “Executive”). The Agreement shall take effect as of February 11, 2019 (the “Effective Date”). Until the Effective Date, the Executive’s July 13, 2018 Offer Letter (the “Initial Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2018 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Employment Agreement (the “Agreement”), effective as of September 10, 2018 (the “Effective Date”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Paul Firuta (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2018 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Employment Agreement (the “Agreement”), effective as of August 15, 2018 (the “Effective Date”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Anthony Gibney (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 10th, 2018 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Employment Agreement (the “Agreement”), effective as of September 10, 2018 (the “Effective Date”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Paul Firuta (the “Executive”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 2nd, 2018 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Joseph Truitt (the “Executive”). The Agreement shall take effect as of the later of the dates set forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s August 4, 2017 Amended and Restated Employment Agreement with the Company (the “Earlier Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2017 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Martha Manning (the “Executive”). The Agreement shall take effect as of the later of the dates set forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s February 1, 2016 Employment Agreement with the Company (the “Initial Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2017 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Milind S. Deshpande, Ph.D. (the “Executive”). The Agreement shall take effect as of the later of the dates set forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s May 28, 2013 Employment Agreement with the Company (the “Initial Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2017 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and David Apelian, MD, Ph.D. (the “Executive”). The Agreement shall take effect as of the later of the dates set forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s May 6, 2013 Employment Agreement with the Company (the “Initial Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2017 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Joseph Truitt (the “Executive”). The Agreement shall take effect as of the later of the dates set forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s April 5, 2011 Employment Agreement with the Company (the “Initial Agreement”) will remain in force and effect and continue to govern the Executive’s employment with the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2017 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
This Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Mary Kay Fenton (the “Executive”). The Agreement shall take effect as of January 1, 2018 (the “Effective Date”). Until the Effective Date, the Executive’s Second Amended and Restated Employment Agreement dated as of March 9, 2010 and Supplemental Severance Agreement dated as of March 9, 2010, both as amended by the Supplemental Terms of Compensation Agreement dated as of April 5, 2011 (collectively, the “Initial Agreement”), will remain in force and effect and continue to govern the Executive’s employment with the Company.
EMPLOYMENT AGREEMENTEmployment Agreement • February 25th, 2016 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of February 1, 2016 (the “Effective Date”), is entered into by Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Martha Manning (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 25th, 2016 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of January 2, 2016 (the “Effective Date”), is entered into by Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Joel Barrish, Ph.D. (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 30th, 2013 • Achillion Pharmaceuticals Inc • Pharmaceutical preparations • Connecticut
THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of the 6th day of May 2013, is entered into by Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and David Apelian, MD, PhD (the “Executive”).
